{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Chromadex Corp. overvalued or undervalued?
As of October 17, 2025, Chromadex Corp. is considered undervalued with an attractive PEG ratio of 0.07 and strong long-term performance, despite a higher P/E ratio compared to some peers and recent short-term underperformance.
Chromadex Corp. Experiences Valuation Adjustment Amid Strong Financial Performance Indicators
Chromadex Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has a notably high P/E ratio of 63 and a Price to Book Value of 18.43. Despite elevated valuation metrics, the company demonstrates strong operational efficiency with a ROCE of 1532.90% and a ROE of 29.28%, highlighting its distinct market position.
Is Chromadex Corp. overvalued or undervalued?
As of October 17, 2025, Chromadex Corp. is considered an attractive investment due to its strong performance metrics, including a high P/E ratio of 63 and a PEG ratio of 0.07, indicating undervaluation relative to growth potential, despite its higher P/E compared to peers and recent volatility.
Is Chromadex Corp. overvalued or undervalued?
As of October 17, 2025, Chromadex Corp. is considered undervalued with an attractive valuation grade, a PEG ratio of 0.07, a high ROCE of 1532.90%, and a competitive P/E ratio of 39.81, significantly outperforming the S&P 500 with a 1-year return of 113.08%.
Chromadex Corp. Experiences Valuation Adjustment Amid Strong Market Performance and Unique Metrics
Chromadex Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $6.93. Over the past year, it achieved a 99.71% return, significantly surpassing the S&P 500. Key metrics include a P/E ratio of 63 and a remarkable ROCE of 1532.90%.
Is Chromadex Corp. technically bullish or bearish?
As of July 14, 2025, Chromadex Corp. shows a mildly bullish trend with mixed technical indicators, having outperformed the S&P 500 with a return of 185.63% compared to 17.14%.
Is Chromadex Corp. overvalued or undervalued?
As of August 6, 2025, Chromadex Corp. is considered overvalued with a P/E ratio of 63 and other high valuation metrics, despite a significant recent stock increase of 185.63%.
Chromadex Corp. Emerges as Multibagger with 172.68% Return Over the Past Year
Chromadex Corp. has recently undergone a revision in its score, reflecting its strong performance metrics and market position. The company has achieved impressive returns, significantly outpacing the S&P 500, while demonstrating consistent growth in net sales and profit. With robust operating cash flow and a solid return on capital employed, Chromadex remains a notable player in the Pharmaceuticals & Biotechnology sector.
Is Chromadex Corp. overvalued or undervalued?
As of October 15, 2023, Chromadex Corp. is considered undervalued with a P/E ratio of 15.2, a P/B ratio of 1.8, and a D/E ratio of 0.5, indicating an attractive investment compared to peers like Herbalife and Amgen.
Is Chromadex Corp. technically bullish or bearish?
As of October 1, 2023, there is not enough technical data for Chromadex Corp. to determine a bullish or bearish outlook.
Who are in the management team of Chromadex Corp.?
As of March 2022, the management team of Chromadex Corp. includes Frank Jaksch (Executive Chairman), Robert Fried (CEO), Kurt Gustafson (Lead Independent Director), and several Independent Directors: Jeffrey Baxter, Stephen Block, Tony Lau, and Steven Rubin. They oversee the company's operations and strategic direction.
What does Chromadex Corp. do?
Chromadex Corporation is a nutraceutical company in the Pharmaceuticals & Biotechnology industry, focusing on research and quality-control products for the natural products sector. As of March 2025, it reported net sales of $30 million and a net profit of $5 million, with a market cap of approximately $1.09 billion.
How big is Chromadex Corp.?
As of Jun 18, Chromadex Corp. has a market capitalization of 1,093.32 million, with net sales of 107.92 million and a net profit of 14.11 million for the latest four quarters. The balance sheet as of December 2024 shows shareholder's funds of 46.09 million and total assets of 68.28 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
